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Gastrointestinal (GI) graft-versus-host disease (GVHD) is one of the most common causes of morbidity and
mortality after allogeneic stem cell transplantation. In addition, cytomegalovirus (CMV) infection of the
gastrointestinal tract can complicate the post-transplantation course of these patients and it can be difﬁcult to
differentiate the 2 diagnoses given that they can present with similar symptoms. We retrospectively analyzed
252 patients who were diagnosed with GI GVHD to evaluate the incidence, risk factors, and outcomes of CMV
viremia and CMV gastroenteritis in these patients. The median age at the time of transplantation was
51 years, 35% were related donor transplantations, and 65% were unrelated donor transplantations. A total of
114 (45%) patients developed CMV viremia at a median of 34 days (range, 14 to 236 days) after trans-
plantation. Only recipient CMV IgG serostatus was signiﬁcantly associated with development of CMV viremia
(P < .001). The incidence of CMV viremia with relation to donor (D) and recipient (R) CMV serostatus sub-
groups was as follows: Dþ/Rþ, 73%; D/Rþ, 67%; Dþ/R, 19%; and D/R, 0. A total of 31 patients were
diagnosed with a biopsy-proven CMV gastroenteritis; 2 patients had evidence of CMV gastroenteritis and
GVHD on the ﬁrst biopsy and 29 on the second biopsy. Median time to development of CMV gastroenteritis
was 52 days (range, 19 to 236 days) after transplantation. Using death as a competing risk, the cumulative
incidence of CMV gastroenteritis at 1 year was 16.4%. The incidence of CMV gastroenteritis in relation to the
donor/recipient serostatus was as follows: Dþ/Rþ, 22%; D/Rþ, 31%; Dþ/R, 12%; and D/RL, 0. Median
follow-up time for the 252 patients was 35.4 (95% CI 23.8 to 44.8) months. The estimated overall survival rate
at 1 and 2 years was .45 (95% conﬁdence interval [CI], .39 to .52) and .39 (95% CI, .33 to .46), respectively. Of
the examined variables, those related to the overall survival were maximal clinical GVHD grade (P < .001) and
development of CMV gastroenteritis (P ¼ .008). Development of CMV viremia was not associated with
increased mortality. In conclusion, CMV gastroenteritis is common complication in patients with GI GVHD
and can adversely affect the prognosis.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Cytomegalovirus (CMV) infection and disease remain a
major cause of morbidity and mortality after allogeneic and
unrelated stem cell transplantation [1-5]. Ganciclovir was
introduced in the late 1980s and is used for both treatmentdgments on page 164.
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ty for Blood and Marrow Transplantation.and prevention of CMV disease [6,7]; however, despite
improvement in treatment, CMV continues to be a major
problem in patients after allogeneic stem cell transplantation
(allo-SCT). One major challenge in the management of these
patients is the differentiation between gastrointestinal (GI)
graft-versus-host disease (GVHD) and CMV gastroenteritis.
These 2 diseases have overlapping symptoms and signs,
which makes treatment decisions difﬁcult without biopsy
conﬁrmation. In addition, the use of CMV viremia to guide
treatment may often be misleading. Use of a preemptive
approach (initiation of ganciclovir therapy based on
D. Bhutani et al. / Biol Blood Marrow Transplant 21 (2015) 159e164160detection of CMV viremia) is currently the strategy used by
most centers as a method to prevent CMV organ disease. But
there are instances in which the CMV organ disease can
develop without preceding CMV viremia. In a study of 14
patients with biopsy-proven CMV gastroenteritis, only 50%
had a positive CMV quantitative PCR (qPCR) before devel-
opment of the CMV colitis [8]. Thus, making the diagnosis of
CMV gastroenteritis in patients with pre-existing GVHD and
worsening symptoms is difﬁcult.
The purpose of our study was to assess the incidence, risk
factors, and prognosis of patients who develop CMV viremia
and CMV gastroenteritis after being diagnosed with GI
GVHD. We also studied the effectiveness of using the CMV
qPCR as a guide to preemptive treatment in these patients
and evaluated the efﬁcacy of repeat gut biopsies for diagnosis
of CMV gastroenteritis in patients with prior biopsy-proven
GI GVHD.
MATERIALS AND METHODS
The Wayne State University institutional review board approved this
study. We retrospectively reviewed charts of patients who underwent allo-
SCT at our institution from January 2005 to December 2011. The eligibility
criteria included development of signs or symptoms of acute or chronic GI
GVHD at any time after transplantation. These included development of
otherwise unexplained nausea, vomiting, anorexia, abdominal pain or
cramps, diarrhea, failure to thrive, and weight loss [9,10]. Grade of GVHD
was determined clinically based on established criteria [9,10]. Variables
assessed for risk factors of the development of CMV viremia and CMV
gastroenteritis were age, gender, race, number of transplantations, donor
(related or unrelated), HLA mismatch, graft source (peripheral blood or
bone marrow), recipient/donor CMV IgG serostatus, underlying diagnosis,
disease status at the time of transplantation, conditioning regimen, GVHD
prophylaxis regimen, thymoglobulin use, acute GVHD grade and peak CMV
qPCR.
CMV Monitoring
All patients were monitored for development of CMV viremia by either
CMV pp65 antigenemia or CMV qPCR on a regular intervals (duration varied
between every 1 to 2 weeks, depending on the clinical situation and fre-
quency of clinic visits) for the duration of post-transplantation immuno-
suppression. Between January and December of 2005, we monitored the
CMV viremia using pp65 antigenemia using direct ﬂuorescence antibody
test. Out of the 252 patients, 33 had monitoring done by the CMV Pp65
antigenemia and the rest were monitored by the CMV PCR. Thereafter, CMV
qPCR was employed as our method of CMV monitoring. CMV viremia was
present if there were greater than 250 copies/mL of CMV DNA. Any patient
with a CMV qPCR of greater than 1000 copies/mL was started on therapy
with i.v. ganciclovir. Patients with 250 to 999 copies/mLwere followed twice
weekly and treatment was initiated if there was a consistent rise of CMV
viremia. Ganciclovir 5 mg/kg intravenous piggyback twice a day was given
as therapy until the CMV qPCR turned negative or at least for 2 weeks if no
signiﬁcant hematologic toxicity was encountered.
GI Biopsies
We attempted to perform routine upper and lower GI biopsies in any
patient suspected of having GI GVHD. Patient without CMV viremiawere not
treated with ganciclovir unless there were histologic documentation of GI
involvement. The decision to do a second GI biopsy in patients with a prior
diagnosis of GI GVHD was based on persistent or worsening of GI symptoms
during or after adequate treatment of GVHD.
Outcomes
Primary event of interest was the development of biopsy-proven CMV
gastroenteritis after the initial diagnosis of GI GVHD. The biopsy diagnosis
was based on immuno-histochemistry on the gut tissue for CMV. The sec-
ondary events of interest were development of CMV viremia, which was
deﬁned by positivity of either CMV pp65 antigenemia or CMV qPCR at any
time after the allogeneic stem cell transplantation and overall survival,
deﬁned as death from any cause after allogeneic stem cell transplantation.
Statistical Analysis
Given that death was a competing event for the other 2 outcomes, we
used a competing risks regression model for the CMV viremia and CMVgastroenteritis outcomes. Standard Cox regression method was used for the
overall survival outcome.
The following algorithm was used to construct the survival phenotype
for both CMV viremia and CMV gastroenteritis outcomes: ﬁrst, for patients
with CMV viremia, the date of ﬁrst day of CMV viremia detected by qPCR or
antigenemia was used as the event date. For the overall survival phenotype,
the date of death was used as the event date for those patients who died. For
those patients who neither had CMV viremia or a death event, the date that
CMV viremiawas last measuredwas used as the censoring date. For the CMV
gastroenteritis outcome, the censoring date was the date of the last biopsy
that was negative for CMV gastroenteritis.RESULTS
Patient Characteristics
Between January 2005 to December 2011, 252 of 780
patients who underwent allo-SCT at our institution had a
clinical diagnosis of GI GVHD, conﬁrmed by histology in 94%.
Three groups were identiﬁed: GI GVHD only, GI GVHD with
CMV viremia, and GI GVHD with CMV viremia and CMV
gastroenteritis. The 3 groups were compared for various
characteristics, as shown in Table 1. There were 9 patients for
which there was no biopsy performed who are still included
in Table 1. They were excluded for analysis of CMV
gastroenteritis.
The median age of the patients was 51 years (range, 20 to
70 years) with an equal distribution of males to females (131
of 121). Amatched sibling donor was used for 89 of 252 (35%)
of the patients and a matched unrelated donor was used in
163 of 252 (65%). Degree of HLA mismatch was 10/10 in 163
of 252 (64%), 9/10 in 57 of 252 (23%), and 8/10 in 29 of 252
(11.5%) patients. Peripheral blood stem cells were used for
transplantation in the majority of patients (238 of 252), bone
marrow harvest was used in 12 patients, and cord blood was
used in 2 patients. A full-intensity conditioning regimen was
used in 178 of 252 (71%) of patients and a reduced-intensity
conditioning regimenwas used in 74 of 252 (29%) of patients.
CMV IgG serostatus of donor (D) and recipient (R) was as
follows: Dþ/Rþ, 78 of 252 (31%); D/Rþ, 67 of 252 (27%);
Dþ/R, 33 of 252 (13%); and D/R, 74 of 252 (29%)
(Table 1). The patient characteristics and demographics were
evenly distributed across 3 groups, with the exception of
CMV serostatus and race (Table 1).GI GVHD Characteristics
Themedian time to development of GI GVHDwas 27 days
(range, 5 to 238 days). Fifteen patients were diagnosed with
hyperacute GVHD starting within 14 days (range, 5 to
14 days) of transplantation. The majority of patients 248
(98%) developed GI GVHD before day 100 after trans-
plantation. Four patients developed GI GVHD after day 100
after transplantation; 2 of these 4 patients had their immu-
nosuppression discontinued because of disease relapse. The
maximal overall clinical grade of II, III, and IV GVHDwas seen
in 37%, 33%, and 30% of patients, respectively. The median
time from stem cell transplantation to ﬁrst GI biopsy was
33 days (range, 12 to 292 days). Histological conﬁrmation of
GI GVHD was conﬁrmed by a biopsy in 239 of 252 (94%) of
patients. Of the 13 patients who did not have histologic
conﬁrmation of GVHD, 9 patients were clinically unstable to
undergo biopsy and 4 patients had normal histology but
were felt to have clinical GI GVHD. Among the patients with a
positive biopsy, the histologic grade of GVHD was grade I, II,
III, and IV in 11%, 27%, 22%, and 40% of patients, respectively.
The degree of correlation between the clinical and histologic
grade of GVHD was moderate, with a Kendall’s tau correla-
tion of .48. Systemic steroids were used in 96% of patients for
Table 1
Patient Characteristics
Characteristic GI GVHD
n ¼ 137
GI GVHD and CMV
Viremia n ¼ 84
GI GVHD and
CMV Viremia and
Gastroenteritis
n ¼ 31
P Value
Age
Mean (SD) 49 (12.4) 50 (10.7) 47 (11.8) .459
Gender
F 62 (.45) 46 (.55) 13 (.42) .300
M 75 (.55) 38 (.45) 18 (.58)
Race
Caucasian 129 (.94) 65 (.77) 22 (.71) <.001
Other 8 (.06) 19 (.23) 9 (.29)
Transplantation type
Related 48 (.35) 26 (.31) 15 (.48) .221
Unrelated 89 (.65) 58 (.69) 16 (.52)
Diagnosis
Leukemia 90 (.66) 56 (.67) 20 (.65) .847
Lymphoma 40 (.29) 23 (.27) 11 (.35)
Myeloma 3 (.02) 3 (.04) 0 (.00)
Other 4 (.03) 2 (.02) 0 (.00)
CMV serostatus
D/R 73 (.53) 1 (.01) 0 (.00) <.001
D/Rþ 19 (.14) 33 (.39) 15 (.48)
Dþ/R 26 (.19) 4 (.05) 3 (.10)
Dþ/Rþ 19 (.14) 46 (.55) 13 (.42)
Disease status
CR 64 (.47) 24 (.29) 17 (.55) .251
PR 9 (.07) 9 (.11) 3 (.10)
SD 18 (.13) 14 (.17) 5 (.16)
PRF 15 (.11) 9 (.11) 2 (.06)
PD 5 (.04) 6 (.07) 1 (.03)
REL 26 (.19) 22 (.26) 3 (.10)
Conditioning regimen
Myeloablative 95 (.69) 60 (.71) 23 (.74) .850
RIC 42 (.31) 24 (.29) 8 (.26)
GVHD Prophylaxis
FK506/MMF 122 (.89) 72 (.86) 26 (.84) .160
FK506/MMF/THYMO* 8 (.06) 6 (.07) 5 (.16)
FK506/MTX 0 (.00) 2 (.02) 0 (.00)
FK506/Siro/THYMO 7 (.05) 4 (.05) 0 (.00)
Thymo-globulin* prophylaxis
Yes 15 (.11) 10 (.12) 5 (.16) .724
No 122 (.89) 74 (.88) 26 (.84)
Maximal clinical GVHD grade
II 51 (.37) 34 (.40) 7 (.23) .435
III 46 (.34) 27 (.32) 11 (.35)
IV 40 (.29) 23 (.27) 13 (.42)
Time to GVHD diagnosis, d
Median (95% CI) estimated from Kaplan-Meier analysis 30 (26-34) 24 (22-28) 24 (22-32) .034
F indicates female; M, male; RIC, reduced-intensity conditioning; CR, complete remission; PR, partial remission; SD, stable disease; PRF, primary refractory; PD,
progressive disease; REL, relapse; FK506, tacrolimus; MMF, mycophenolate mofetil; Thymo, thymoglobulin; MTX, methotrexate; Siro, sirolimus.
Data presented are n (%), unless otherwise indicated.
* Thymoglobulin prophylaxis for GVHD.
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steroids from transplantation was 28 days (range, 5 to 238)
and the interval from diagnosis of GI GVHD to starting sys-
temic steroids was 1 day (range, 0 to 31 days). Two patients
had evidence of CMV gastroenteritis along with GVHD on
ﬁrst biopsy and both of them had evidence of CMV viremia
before the GI biopsy.
Second-line therapy for GVHD was used in 73 of 252
(29%) patients and consisted of sirolimus in 27 of 73 (35%),
antithymocyte globulin in 11 of 73 (15%), etanercept in 22 of
73 (30%), mycophenolate mofetil in 7 of 73 (10%), rituximab
in 4, inﬂiximab in 1, and extracorporeal photopheresis in 1
patient. Median time to starting the second-line therapy was
42 days (range, 22 to 127 days) from the day of trans-
plantation. Out of these 73 patients, 32 (43%) patients had
evidence of CMV viremia and 7 patients (10%) developed
CMV gastroenteritis. Among the patients who did not getsecond-line GVHD (179 patients) therapy, the incidence of
CMV viremia was 83 of 179 (46%) and the incidence of CMV
gastroenteritis was 24 of 179 (13%). We did not include the
second-line therapy as a variable in our multivariable ana-
lyses given that this particular variable can not be predicted
at the time of the transplantation and could be affected by
many other concurrent variables.
CMV Viremia
A total of 114 of 252 (45%) patients with GI GVHD devel-
oped CMV viremia a median 34 days (range, 14 to 236 days)
after transplantation. Out of the 252 patients, 33 patients had
monitoring done by the CMV Pp65 antigenemia and the rest
were monitored by the CMV PCR. Of the 114 patients who
developed CMV viremia, 18 (15%) developed viremia before
the diagnosis of GI GVHD, 8 (7%) developed both concomi-
tantly, and the remaining 88 (78%) developed it after GI
D. Bhutani et al. / Biol Blood Marrow Transplant 21 (2015) 159e164162GVHD. Out of the 114 patients, 109 were treated with sys-
temic steroids at some time after the transplantation. Five
patients were not given systemic steroids because the
symptoms of GVHD were mild and short lasting. The ma-
jority of these patients, 83 out of 109 (76%), developed CMV
viremia after starting systemic steroid therapywith amedian
duration of 13 days (range, 1 to 90) between starting steroid
therapy and the ﬁrst detection of CMV viremia. Only 26 of
109 (24%) patients had evidence of CMV viremia before
steroid therapy.
The incidence of CMV viremia with relation to donor and
recipient CMV serostatus subgroups was as follows: Dþ/Rþ,
73%; D/Rþ, 67%; Dþ/R, 19%; and D/R, 0 (Figure 1). In
the univariate competing risk model, only 2 variables (vari-
ables are detailed in Methods) were signiﬁcantly associated
with development of CMV viremia: recipient CMV IgG
serostatus and race. Multivariable modeling resulted in only
recipient CMV IgG serostatus signiﬁcantly associated with
development of CMV viremia (P < .001).Figure 2. Association between CMV serostatus and CMV gastroenteritis esti-
mated from a competing risk model with death a competing event. Dþ/Rþ,
22%; D/Rþ, 31%; Dþ/R, 12%; D/R, 0.CMV Gastroenteritis
A total of 31 patients were diagnosed with biopsy-proven
CMV gastroenteritis; only 2 patients had evidence of CMV
gastroenteritis and GVHD on the ﬁrst biopsy, whereas 29 had
CMV gastroenteritis on a second biopsy. Median time to
development of CMV gastroenteritis was 52 days (range, 19
to 236 days) after transplantation.
A total of 116 of 252 (45%) patients underwent a second
endoscopy because of persistent or worsening GI symptoms
after treatment for GI GVHD at a median of 44 days (range, 8
to 292 days) from the clinical diagnosis of GVHD. In the pa-
tients without CMV gastroenteritis, 17 (14%) had normal bi-
opsies and 70 (60%) had persistent GVHD. In the 29 patients
with CMV gastroenteritis on the second biopsy, 21 had no
evidence of GVHD whereas 8 had evidence of GVHD and
CMV.
Using death as a competing risk, the cumulative incidence
of CMV gastroenteritis at 1 year was 16.4%. The incidence of
CMV gastroenteritis in relation to the donor/recipientFigure 1. Association between CMV serostatus and incidence of CMV viremia,
estimated from a competing risk model with death as a competing event. Dþ/
Rþ, 73%; D/Rþ, 67%; Dþ/R, 19%; and D/R zero.serostatus was as follows: Dþ/Rþ, 22%; D/Rþ, 31%; Dþ/R,
12%; D/R, 0 (Figure 2).
Relationship between CMV Viremia and CMV
Gastroenteritis
In 28 of 31 patients, CMV viremia was detected a median
of 9 days (range, 1 to 36 days) before developing CMV
gastroenteritis. In 3 patients, the viremia was detected after
the diagnosis of CMV gastroenteritis. This suggests that in a
signiﬁcant proportion of these patients, the development of
CMV viremia and gastroenteritis coincide.
In the univariate analysis (done only on patients who had
at least 1 GI biopsy, n ¼ 243), risk factors for development of
CMV gastroenteritis were recipient CMV IgG seropositivity
(P < .001), development of CMV viremia (P < .001), race
(Caucasian versus non-Caucasian) (P ¼ .027), transplantation
type (unrelated versus related) (P ¼ .044), and log of CMV
qPCR peak (P < .001). On multivariate analysis, only the
recipient CMV IgG seropositivity and development of CMV
viremia remained statistically associated with development
of CMV gastroenteritis. Degree of HLA mismatch had no
impact on CMV viremia or CMV gastroenteritis outcomes.
Because the CMV qPCR peak would occur only in those
patients who had a viremia event, we excluded this variable
from the above multivariate analysis. Higher peak of CMV
qPCR was related to increased risk of development of CMV
gastroenteritis. For each unit increase (on the log scale) of
CMV qPCR peak, the hazard of CMV gastroenteritis increased
by 1.33 (95% conﬁdence interval [CI], 1.18 to 1.50).
Effect of Preemptive Ganciclovir Therapy
Overall, 114 patients developed CMV viremia and 107
were treated with ganciclovir with a median duration from
detection of CMV viremia to the initiation of ganciclovir of
3 days (range, 0 to 13 days). All except 4 patients had a
response to use of ganciclovir with decrease in qPCR.
In patients who developed CMV gastroenteritis, only 19 of
31 could be started on preemptive therapy before the diag-
nosis of CMV gastroenteritis, given that in many patients the
time between detection of CMV viremia and diagnosis of
Table 2
Causes of Death
Cause of death n of 157 (%)
Acute GVHD 59 (38%)
Chronic GVHD 15 (9.5%)
Disease relapse 34 (21.6%)
Bacterial infections 17 (11%)
Viral and fungal infections 18 (11%)
Multiorgan failure 9 (5.7%)
Hemorrhage 3 (2%)
Unknown 2 (1%)
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who were able to start the preemptive therapy based on the
CMV viremia, the median duration from the start of ganci-
clovir to the biopsy conﬁrming the diagnosis of CMV
gastroenteritis was only 5 days (range,1 to 26 days) and in 14
of 19 patients, this difference was less than 10 days. Overall,
only 5 patients were able to receive preemptive ganciclovir
for more than 10 days (range, 10 to 26 days) before being
diagnosed with CMV gastroenteritis.
Survival
The median (95% CI) follow-up time for the overall sur-
vival endpoint, calculated using the inverse Kaplan-Meier
method was 35.4 (95% CI, 23.8 to 44.8) months. The esti-
mated overall survival rate at 1 and 2 years was .45 (95% CI,
.39 to .52) and .39 (95% CI, .33 to .46), respectively. Non-
relapse mortality, estimated using competing risks, at 1 and
2 years was .48 (95% CI, .42 to .55) and .51 (95% CI, .45 to.58),
respectively. The detailed causes of death are summarized in
Table 2.
In multivariable analysis, the variables signiﬁcantly
related to the overall survival were maximal clinical GVHD
grade (P < .001) (Figure 1) and development of CMV
gastroenteritis (P ¼ .008). The median survival of patients
with various clinical grades of GVHDwas as follows: grade II:
not reached range, 23.69 to not reached), grade III: 10.97
(range, 4.93 to 40.34) months, grade IV: 2.12 (range, 1.38 to
3.09) months (Figure 3). Development of CMV viremia was
not associated with increased mortality.
The estimated hazard ratio for mortality with develop-
ment of CMV gastroenteritis was 1.83 (95% CI, 1.17 to 2.87). Of
31 patients who developed CMV gastroenteritis, only 7 areFigure 3. Overall survival based on the maximal overall clinical grade of
GVHD.alive at the last follow-up, corresponding to an overall
mortality rate of 77% in these patients. In patients who
developed CMV gastroenteritis, the attributed causes of
death were CMV infection in 4 of 24, acute GVHD in 7 of 24,
chronic GVHD in 2 of 24, bacterial infections in 4 of 24, fungal
infection in 1 of 24, disease recurrence in 3 of 24, diffuse
alveolar hemorrhage in 1 of 24, and multi-organ failure in 2
of 24 patients.
DISCUSSION
GI GVHD continues to be amajor complication of allo-SCT,
being difﬁcult to manage with high morbidity and mortality.
CMV viremia and disease can complicate the post-
transplantation course of patients undergoing allo-SCT.
Before the introduction of ganciclovir therapy, the inci-
dence of CMV viremia in such patients ranged from 40% to
69% in CMV-seropositive patients [1-3], with an incidence of
CMV organ disease of about 15% to 25% of such patients
[1,4,5].
Ganciclovir has shown effectiveness in both treatment
and prevention of CMV disease [6,7] in bone marrow trans-
plantation patients. As part of the preventive strategies,
ganciclovir has been used both as prophylactic and pre-
emptive therapy. A randomized trial [11] comparing the
prophylactic versus the preemptive ganciclovir therapy
showed a reduction in the incidence of CMV disease in the
prophylaxis group for the duration of the prophylactic ther-
apy, but on longer follow-up there was no difference in the 2
groups in terms of the incidence of CMV disease. In addition,
patients in the ganciclovir prophylaxis group had a higher
incidence of neutropenia and a higher incidence of bacterial
and fungal infections [11]. Thus, the preemptive use of gan-
ciclovir guided by monitoring of CMV viremia measured by
antigenemia or qPCR has become standard of care in this
setting.
Our study represents one of the largest studies describing
the pattern of CMV viremia and infection in patients with GI
GVHD. Almost one half of our patients (114 [45%]) with GI
GVHD developed CMV viremia. On multivariate analysis,
only the recipients who had CMV IgG seropositivity and
development of CMV viremia remained statistically associ-
ated with development of CMV gastroenteritis. Cho et al. [12]
described their single-center experience of CMV viremia and
CMV disease in patients with GI GVHD. Their study of 103
patients showed an overall incidence of CMV disease of 25%,
but only 42% of patients with CMV gastroenteritis had pre-
ceding evidence of CMV viremia by qPCR. This is different
from our results given the fact that majority of our patients
(28 of 31) who developed CMV gastroenteritis had preceding
evidence of CMV viremia. We think this difference likely
represents the frequency of CMV qPCR monitoring, given
that in their study the qPCRwas checked weekly to biweekly,
as opposed to weekly in our study. Similar to our study, the
risk factors associated with poor survival were severity of
GVHD and development of CMV gastroenteritis.
The overall response rates to initial GVHD treatment with
steroids is in the range of 50% with a slightly lower response
rates in patients with lower GI GVHD [13,14]. Our data show
similar results, with about 46% of patients with GI GVHD not
responding to the steroid therapy. On repeat GI biopsies in
patients with less than optimal response to GVHD treatment,
about one quarter of those patients have CMV infection in the
GI tract. Although most of these patients had evidence of
CMV viremia concurrently with the GI infection, diagnosis of
CMV organ disease had a signiﬁcant impact on the patient
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of immunosuppression. In addition, recommended duration
of therapy is longer in patients with CMV organ disease than
it is in those just with viremia [15]. So overall, it remains
imperative to rebiopsy patients who have a less than optimal
response to initial treatment of GI GVHD.
Since the introduction of the preemptive ganciclovir
therapy, the incidence of the viremia, as expected, remains
unchanged in recipients of allo-SCT but there has been sig-
niﬁcant decline in the incidence of early (within ﬁrst
100 days) onset CMV disease [16]. Late onset CMV disease
after the preemptive antiviral therapy is stopped continues
to be signiﬁcant, with an overall incidence of about 10% [17].
Recipient CMV serostatus remains the most important risk
factor for development of CMV viremia as well as disease
[1,2,17]. The other important risk factor identiﬁed is devel-
opment of GVHD and associated use of immunosuppression
[11,18,19]. Other risk factors identiﬁed are use of antithy-
mocyte globulin [11], conditioning regimens containing
campath-1H/ﬂudarabine [20], high CMV viral load [21],
lymphocytopenia, and CMV-speciﬁc T cell immunodeﬁ-
ciency [22].
Given that all of our patients had underlying GVHD and
exposure to immunosuppression, the risk factors for devel-
opment of CMV gastroenteritis that we could identify were
the recipient and donor’s CMV IgG seropositivity, CMV
viremia, and a high titer of CMV peak qPCR. It is important to
note that the patient subgroups of CMV serostatus D/Rþ
had a higher incidence of CMV gastroenteritis compared
with Dþ/Rþ patients. This likely reﬂects the effect of lack of T
cell immunity of the donor cells against CMV as they engraft
the recipient [22]. The majority of the patients developed
CMV viremia after the start of steroid therapy, which is a
known risk factor for the CMV viremia [23].
We used preemptive ganciclovir therapy in our patients
as guided by CMV viremia. The incidence of CMV viremia in
our study was about 70% in CMV-seropositive patients. There
appear to be a close temporal relationship between the
development of CMV gastroenteritis and CMV viremia. In a
signiﬁcant majority of these patients, the time lag between
the diagnosis of CMV viremia and the diagnosis of CMV
gastroenteritis was quite short, and, in addition, further
inﬂuenced somewhat by the logistics of arranging for the
biopsy as well. Three patients did not have evidence of CMV
viremia at the time they were diagnosed with CMV gastro-
enteritis. Thus, in these patients, the preemptive approach
may not be an effective strategy and identifying a high-risk
group for use of prophylactic therapy might be more suit-
able in such patients. According to our data, such a high-risk
group could be described as patients with negative donor
and positive recipient (D/Rþ) CMV IgG serostatus and with
GVHD requiring use of systemic steroids.
In conclusion, CMV infection is a substantial problem in
patients with GI GVHD and does affect the survival of this
groupof patients. Aggressivemonitoring for CMVviremia and
organ biopsies are imperative to make timely treatment de-
cisions and help guide immunosuppression. The question of
identifying high-risk groups and use of prophylactic therapy
in such groups should be pursued in further research.ACKNOWLEDGMENTS
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